KalVista Pharmaceuticals, a clinical stage pharmaceutical company, has announced that it will be presenting at the Cantor Global Healthcare Conference on September 27th, 2023. The presentation will take place in New York, NY at 4:10 p.m. ET. A live webcast of the presentation will be available on the company’s website, with an audio archive of the presentation available for 30 days following the event.
KalVista Pharmaceuticals is dedicated to the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. One of their key focuses is the development of sebetralstat, an oral on-demand therapy for hereditary angioedema (HAE) attacks. The company has reached its target enrollment for the phase 3 KONFIDENT clinical trial of sebetralstat.
In addition to sebetralstat, KalVista Pharmaceuticals is also working on an oral Factor XIIa inhibitor program, which represents a new generation of therapies for HAE and other diseases. These programs aim to improve the treatment options available for individuals living with HAE and other related conditions.
For more information about KalVista Pharmaceuticals and their ongoing research and development efforts, please visit their website.
Source: [Business Wire]
